National biotech sector ‘awakening’ to Colorado’s ascension, challenges remain
AURORA — Colorado’s status as a top-notch biotechnology hub is not much of a secret anymore, but the sector is still experiencing some growing pains as it emerges as a leader on the world stage.
In recent years, there’s been an “awakening” within the broader life-sciences sector that the Centennial State’s companies, labs, incubators, research institutions and schools punch well above their weight, Fitzsimons Innovation Community CEO Steve VanNurden said Wednesday during an industry panel at the University of Colorado Anschutz campus in Aurora. The panel was moderated by Fitzsimons business development vice president April Giles.
Colorado Bioscience Association CEO Elyse Blazevich…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Arca Biopharma has completed its merger with Oruka Therapeutics Inc.
